Modulators of 5-HT receptors and methods of use thereof

US9701679B2 · kind B2 · utility

Assignees

• Abb Vie Deutschland Gmbh & Co. KG · DE
• Abb Vie Inc. · US

Inventors

• Ying Wang · Lake Villa, US
• Jason T. Brewer · Zion, US
• Irini Akritopoulou-Zanze · Libertyville, US
• Stevan W. Djuric · Libertyville, US
• Bhadra Shelat · Lake Forest, US
• Frauke Pohlki · Wiesbaden, DE
• Wilfried Braje · Ludwigshafen, DE
• Ana-Lucia Relo · Ludwigshafen, DE

Key dates

• Filing date: Sep 30, 2014
• Grant date: Jul 11, 2017
• Expiry date: Sep 30, 2034

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02E60/32
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I)wherein R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.